Obermatt
See Similar Stocks →

BillionToOne

NSQ:BLLN · US0901681058
Health Care Providers & ServicesSmall

360

55
EV / EBIT8
Price / Owner Earnings3
Owner Earnings Yield36
Dividend Yield1
Price/Sales7
EV / Gross Profit3
Price/Book13
Return on Capital58
Cash Return on Capital53
Return on Equity59
EBIT Margin75
Gross Profitability61
Cash Conversion28
Accruals38
Owner Earnings Margin70
Sales growth96
Profit growth56
Reinvestment20
Price momentum20
Debt load67
Refinancing47
Debt Payback100
Liquidity98
Analyst ratings36
Opinion Changes50
Price Target Upside49
Market mood13
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

BillionToOne generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2016
Employees655
Websitebilliontoone.com
ISINUS0901681058
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Artificial IntelligenceBiomedical EngineeringHealth DiagnosticsComputer VisionGeneticsMachine LearningGenetic DisorderOncologyBiotechnologyMedical

Description

BillionToOne, Inc. (BillionToOne) is a precision diagnostics company that quantifies biology to create molecular diagnostics. The company’s proprietary molecular counting platform is designed to detect and measure DNA molecules at the single-count l…

Analysis

Hope premium

BillionToOne, Inc. carries what we call a hope premium: an average business trading at an ambitious price.

The price is expensive. You pay 220.5× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is solid and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
11
2026

All-time high

28

Mar 2026

All-time low

11

Jun 2026

Average rank

20

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
7
—
—
—
Price/Earnings
8
—
—
—
Price/Book
13
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
1
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare BillionToOne with its peers
Vertex Pharmaceuticals
NSQ:VRTX
63
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Castle Biosciences
NMQ:CSTL
10
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Guardant Health
NSQ:GH
14
CountryUSA
IndustryHealth Care Providers & Services
SizeLarge
Full Stock Analysis →
NeoGenomics
NAQ:NEO
31
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Pediatrix Medical
NYQ:MD
90
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Veracyte
NMQ:VCYT
80
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →